Guide to Ocrevus Infusion Preparation and Monitoring

Ocrevus, also known as ocrelizumab, is an intravenous medicine used for certain forms of multiple sclerosis. Because it affects B cells involved in immune function, appropriate screening and monitoring are important before and during treatment. The current U.S. prescribing information recommends specific assessments before the first dose and safety checks before subsequent infusions.

Ocrevus Infusion Preparation and Pre Infusion Checks

Preparation begins before the infusion is started. Healthcare professionals assess whether the patient has an active infection and may delay treatment if an infection is present. Before the first dose, hepatitis B screening, quantitative serum immunoglobulin testing, and liver-related laboratory assessments are recommended. Vaccination status is also reviewed because certain vaccines should be administered before treatment begins.

Premedication is used to reduce the frequency and severity of infusion-related reactions. The prescribing information recommends an intravenous corticosteroid before each infusion and an antihistamine shortly before treatment. The exact medication, dose, and timing are determined by the healthcare professional according to the patient's age, weight, and treatment plan.

Important preparation considerations include:

• Reviewing the patient's current health and infection status before every infusion.
• Checking for a history of serious allergic or infusion reactions.
• Completing recommended hepatitis B screening before the first dose.
• Reviewing immunoglobulin levels and relevant laboratory results.
• Reviewing vaccination history and timing.
• Administering recommended premedication before the infusion.
• Confirming the prescribed Ocrevus dose and infusion schedule.

Ocrevus Infusion Monitoring and Safety Considerations

During an Ocrevus infusion, healthcare professionals monitor patients for signs of infusion reactions. These reactions can include itching, rash, hives, coughing, wheezing, throat irritation, dizziness, nausea, headache, flushing, shortness of breath, or changes in heart rate. If a reaction occurs, the healthcare professional may slow or temporarily stop the infusion and provide appropriate treatment depending on its severity.

Patients are also observed after the infusion. Current prescribing information states that patients should be monitored during the infusion and for at least one hour after completion. Patients should also understand that some symptoms may develop after leaving the infusion setting and should promptly contact their healthcare provider if concerning symptoms occur.

Monitoring generally focuses on:

• Changes in breathing, blood pressure, heart rate, or overall condition.
• Skin reactions such as itching, redness, rash, or hives.
• Symptoms involving the throat, face, or airway.
• Dizziness, headache, nausea, fever, or unusual tiredness.
• Signs of infection that may require medical assessment.
• Any symptoms suggesting a serious infusion reaction.

Ocrevus infusion preparation and monitoring are important parts of safe administration. Screening before treatment, appropriate premedication, careful observation during administration, and post-infusion monitoring help healthcare professionals identify potential problems promptly. Patients should provide complete information about infections, medications, vaccinations, previous reactions, and other relevant health concerns before receiving treatment. This information is educational only and is not a substitute for advice or instructions from a qualified healthcare professional.